PULSE BIOSCIENCES, INC. 8-K

What Happened
Pulse Biosciences, Inc. (PLSE) filed an 8-K on January 14, 2026 disclosing that it posted an updated investor presentation on its website. The Investor Deck outlines recent progress in the company’s product development programs for its proprietary nPulse Vybrance Percutaneous Electrode, the nPulse Cardiac Clamp, and the nPulse Cardiac Catheter. The company said it expects to use this presentation, in whole or in part and possibly with modifications, in communications with investors, analysts and others. The deck is attached to the filing as Exhibit 99.1.

Key Details

• Filing date: January 14, 2026 (Form 8-K, Item 7.01 Regulation FD Disclosure).
• Attached exhibit: Investor Deck dated January 2026 (Exhibit 99.1).
• Programs highlighted: nPulse Vybrance Percutaneous Electrode, nPulse Cardiac Clamp, nPulse Cardiac Catheter.
• No financial results, material agreements, or executive changes were reported in this filing.

Why It Matters
This disclosure is a Regulation FD update that makes the company’s recent product development messaging broadly available to all investors and analysts. For retail investors, the deck is a primary source to review the company’s stated progress on its nPulse pipeline and upcoming commercialization or clinical milestones. Because the filing contains presentation materials rather than new financial data or formal announcements of deals or trial results, investors should review the attached Investor Deck for details and await future filings or company statements for material milestones or financial impacts.